179 related articles for article (PubMed ID: 34046928)
1. Race/ethnicity and underlying disease influences hematopoietic stem/progenitor cell mobilization response: A single center experience.
Uzoka C; Liu LC; Park Y; Lin Y; Patel P; Campbell-Lee S; Sweiss K; Wang X; Tepak E; Peace D; Saraf S; Rondelli D; Mahmud N
J Clin Apher; 2021 Aug; 36(4):634-644. PubMed ID: 34046928
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
3. Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis.
Hsu JW; Wingard JR; Logan BR; Chitphakdithai P; Akpek G; Anderlini P; Artz AS; Bredeson C; Goldstein S; Hale G; Hematti P; Joshi S; Kamble RT; Lazarus HM; O'Donnell PV; Pulsipher MA; Savani BN; Schears RM; Shaw BE; Confer DL
Biol Blood Marrow Transplant; 2015 Jan; 21(1):165-71. PubMed ID: 25316111
[TBL] [Abstract][Full Text] [Related]
4. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.
Sheppard D; Tay J; Palmer D; Xenocostas A; Doulaverakis C; Huebsch L; McDiarmid S; Tinmouth A; Mallick R; Martin L; Birch P; Hamelin L; Allan D; Bredeson C
Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic progenitor cell mobilization is more robust in healthy African American compared to Caucasian donors and is not affected by the presence of sickle cell trait.
Panch SR; Yau YY; Fitzhugh CD; Hsieh MM; Tisdale JF; Leitman SF
Transfusion; 2016 May; 56(5):1058-65. PubMed ID: 27167356
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
7. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
8. Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation.
Engelhardt M; Bertz H; Wäsch R; Finke J
Ann Hematol; 2001 Apr; 80(4):201-8. PubMed ID: 11401085
[TBL] [Abstract][Full Text] [Related]
9. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.
Holmberg LA; Linenberger M; Connelly-Smith L
Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104
[TBL] [Abstract][Full Text] [Related]
10. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
[TBL] [Abstract][Full Text] [Related]
11. Stem Cells mobilization and collection in allogeneic related and unrelated donors: a single center experience with focus on plerixafor.
Marcon C; Bertone A; Mauro S; Mestroni R; Battaglia G; Pizzano U; Facchin G; De Martino M; Isola M; Patriarca F; Barillari G; Savignano C
Transfus Apher Sci; 2023 Dec; 62(6):103845. PubMed ID: 37953206
[TBL] [Abstract][Full Text] [Related]
12. A comparison of four leukapheresis methods to harvest an optimal dose of CD34+ cells: A single center experience.
Lin Y; Park Y; Khanal A; Campbell-Lee S; Liu L; Chen Z; Patel P; Vidanovic V; Sweiss K; Irene G; Peace D; Rondelli D; Mahmud N
Eur J Haematol; 2022 Dec; 109(6):711-718. PubMed ID: 36030395
[TBL] [Abstract][Full Text] [Related]
13. African American adult apheresis donors respond to granulocyte-colony-stimulating factor with neutrophil and progenitor cell yields comparable to those of Caucasian and Hispanic donors.
Carilli AR; Sugrue MW; Rosenau EH; Chang M; Fisk D; Medei-Hill M; Williams K; Wiggins L; Wingard JR
Transfusion; 2012 Jan; 52(1):166-72. PubMed ID: 21790625
[TBL] [Abstract][Full Text] [Related]
14. Unraveling stem cell and progenitor subsets in autologous grafts according to methods of mobilization: implications for prediction of hematopoietic recovery.
Roug AS; Hokland LB; Segel E; Nielsen K; Toft-Petersen M; Van Kooten Niekerk PB; Hokland P; Nederby L
Cytotherapy; 2014 Mar; 16(3):392-401. PubMed ID: 24424268
[TBL] [Abstract][Full Text] [Related]
15. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
[TBL] [Abstract][Full Text] [Related]
16. Plerixafor added to G-CSF allows mobilization of a sufficient number of hematopoietic progenitors without impacting the efficacy of TCR-alpha/beta depletion in pediatric haploidentical and genoidentical donors failing to mobilize with G-CSF alone.
Kurnikova E; Trakhtman P; Pershin D; Ilyushina M; Khismatullina R; Maschan M; Novichkova G; Maschan A
J Clin Apher; 2021 Aug; 36(4):547-552. PubMed ID: 33682959
[TBL] [Abstract][Full Text] [Related]
17. Mobilization kinetics of CD34+ hematopoietic stem cells stimulated by G-CSF and cyclophosphamide in patients with multiple sclerosis who receive an autotransplant.
Jaime-Pérez JC; Gómez-Galaviz AC; Turrubiates-Hernández GA; Picón-Galindo E; Salazar-Riojas R; Méndez-Ramírez N; Gómez-Almaguer D
Cytotherapy; 2020 Mar; 22(3):144-148. PubMed ID: 32057615
[TBL] [Abstract][Full Text] [Related]
18. Effect of high-dose plerixafor on CD34
Pantin J; Purev E; Tian X; Cook L; Donohue-Jerussi T; Cho E; Reger R; Hsieh M; Khuu H; Calandra G; Geller NL; Childs RW
Haematologica; 2017 Mar; 102(3):600-609. PubMed ID: 27846612
[TBL] [Abstract][Full Text] [Related]
19. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors.
Newell LF; Shoop KM; Knight RJ; Murray SN; Kwock RP; Jacoby CE; Slater S; Allen BE; Ottowa C; Cota B; Appel PL; Cook RJ; Maziarz RT; Meyers G
Cytotherapy; 2019 Jul; 21(7):725-737. PubMed ID: 31085121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
